A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 23 Jul 2019
Price : $35 *
At a glance
- Drugs IMX-110 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Immix Biopharma Australia
- 23 Jul 2019 According to an Immix Biopharm media release, the company is still finalizing the sites in the United States that will participate in this trial. Also, the company is expanding its Series A financing to add more patients in this study.
- 23 Jul 2019 According to an Immix Biopharma media release, the company announced it has received a letter from FDA authorizing it to proceed with expanding this trial to the United States under an IND.
- 23 Jul 2019 Interim results of the Ib portion published in the Immix Biopharma media release